t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature

Leuk Res. 2011 Sep;35(9):e151-3. doi: 10.1016/j.leukres.2011.05.013. Epub 2011 May 31.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzenesulfonates / therapeutic use*
  • Chromosomes, Human, Pair 22 / genetics
  • Chromosomes, Human, Pair 8 / genetics
  • Diagnosis, Differential
  • Humans
  • Myeloproliferative Disorders / diagnosis*
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics*
  • Niacinamide / analogs & derivatives
  • Oncogene Proteins, Fusion / genetics
  • Oncogene Proteins, Fusion / physiology
  • Phenylurea Compounds
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Proto-Oncogene Proteins c-bcr / genetics
  • Pyridines / therapeutic use*
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics
  • Sorafenib
  • Translocation, Genetic

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Oncogene Proteins, Fusion
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib
  • FGFR1 protein, human
  • Receptor, Fibroblast Growth Factor, Type 1
  • BCR protein, human
  • Proto-Oncogene Proteins c-bcr